- Conditions
- Prevention of Pregnancy
- Interventions
- Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 938 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 33,598
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- XOMA 052, Placebo
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 2
- States / cities
- Clearwater, Florida • Middleburg Heights, Ohio
- Conditions
- Keratoconus
- Interventions
- The VEGA UV-A Illumination System, Riboflavin
- Device · Drug
- Lead sponsor
- Topcon Medical Systems, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Bloomington, Minnesota + 4 more
- Conditions
- Surgical Procedure, Unspecified
- Interventions
- ViKY UP
- Device
- Lead sponsor
- EndoControl
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Charlotte, North Carolina
- Conditions
- Emergency Contraception
- Interventions
- CDB-2914
- Drug
- Lead sponsor
- HRA Pharma
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 17
- States / cities
- San Jose, California • Denver, Colorado • Miami, Florida + 14 more
- Conditions
- Safety
- Interventions
- PEP (Purified Exosome Product)
- Drug
- Lead sponsor
- Clinical Testing of Beverly Hills
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Encino, California
- Conditions
- Allergic Reactions
- Interventions
- Neffy, Adrenaline
- Drug
- Lead sponsor
- ARS Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Glenview, Illinois + 3 more
- Conditions
- Social Anxiety Disorder
- Interventions
- Quetiapine
- Drug
- Lead sponsor
- Cambridge Health Alliance
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- CLAAS, WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
- Device
- Lead sponsor
- Conformal Medical, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
- Conditions
- Dermatitis, Atopic
- Interventions
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Henrico, Virginia
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Clazosentan, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more
- Conditions
- Gingival Recession
- Interventions
- Gintuit, Autologous palatal tissue
- Device · Other
- Lead sponsor
- Organogenesis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas + 1 more
- Conditions
- Smallpox
- Interventions
- Wetvax (APSV)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 32 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 4
- States / cities
- Oakland, California • Iowa City, Iowa • Nashville, Tennessee + 1 more
- Conditions
- Hypertension
- Interventions
- QGC001
- Drug
- Lead sponsor
- Quantum Genomics SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Port Orange, Florida
- Conditions
- Irritable Bowel Syndrome, Diarrhea
- Interventions
- Donor Fecal Microbiota Transplantation, Autologous Fecal Microbiota Transplantation
- Biological
- Lead sponsor
- Madhusudan (Madhu) Grover, MBBS
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- AK006 IV
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Bakersfield, California • Upland, California + 6 more
- Conditions
- Venous Thromboembolism
- Interventions
- Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Advanced Cancer
- Interventions
- 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
- Drug
- Lead sponsor
- DEKK-TEC, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 3
- States / cities
- New Orleans, Louisiana • Detroit, Michigan
- Conditions
- Celiac Disease
- Interventions
- 4 dose levels of ALV003
- Drug
- Lead sponsor
- Alvine Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
- Interventions
- TYRA-300
- Drug
- Lead sponsor
- Tyra Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more
- Conditions
- Melanoma (Skin)
- Interventions
- Synchrotope TA2M
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Male Pattern Hair Loss, Androgenetic Alopecia, Male Pattern Baldness
- Interventions
- Post-Laser Minoxidil 2%, At-Home Minoxidil 5%, Laser, Post-laser 5mg minoxidil, Post-laser 10mg minoxidil, Post-laser 20mg minoxidil
- Drug · Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years to 65 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Psoriasis
- Interventions
- Placebo for Risankizumab, Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more
- Conditions
- Non-syndromic Retinitis Pigmentosa
- Interventions
- Gene therapy: GS030-DP AND Medical device: GS030-MD
- Combination Product
- Lead sponsor
- GenSight Biologics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania